Impact of age on plasma vaspin concentration in a group of normal Chinese people by unknown
1 3
J Endocrinol Invest (2017) 40:143–151
DOI 10.1007/s40618-016-0533-6
ORIGINAL ARTICLE
Impact of age on plasma vaspin concentration in a group 
of normal Chinese people
X. Xu1 · J. Wen1 · Y. Lu1 · H. Ji1 · J. Zhuang1 · Y. Su1 · B. Liu1 · H. Li1 · Y. Xu1 
Received: 7 June 2016 / Accepted: 14 August 2016 / Published online: 7 September 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
multiple regression analysis showed that age contributed 
7.6 % on plasma vaspin level.
Conclusion Vaspin level increased with ageing, independ-
ent of sex, indices of glucose metabolism, lipid profile and 
other markers of adiposity.
Keywords Adipokines · Vaspin · Ageing · Insulin 
resistance
Abbreviations
TNF-α  Tumour necrosis factor-α
BMI  Body mass index
HOMA-IR  Homoeostasis model of assessment–insulin 
resistance
IR  Insulin resistance
WBC  White blood cell count
hsCRP  High-sensitive C-reactive protein
FPG  Fasting plasma glucose
ALT  Alanine aminotransferase
BUN  Blood urea nitrogen
TC  Total cholesterol
LDL-C  Low-density lipoprotein cholesterol
HDL-C  High-density lipoprotein cholesterol
TG  Triglycerides
EGTA  Ethylene diamine tetraacetic acid
Introduction
Adipose tissue, previously perceived to be a storage reser-
voir of fat, is now recognized as an active endocrine organ 
[1, 2]. Adipose tissue secretes a number of adipocyte-spe-
cific cytokines (adipokines), which played important roles 
in the process of the metabolism, inflammation, cell pro-
liferation and apoptosis [3, 4]. Ageing is correlated with an 
Abstract 
Purpose Visceral adipose tissue-derived serine protease 
inhibitor (vaspin) is an adipocytokine with insulin-sensi-
tizing effects. Accumulating data implied that vaspin rep-
resents a compensatory mechanism but it is unknown how 
vaspin change during ageing. This study was designed to 
examine the correlation between plasma vaspin and age in 
a group of normal Chinese people.
Methods A total of 191 Chinese volunteers aged 
19–80 years were enrolled into four groups based upon age 
quartiles (19–35, 36–50, 51–65 and 66–80 years). Demo-
graphic, anthropometric, metabolic covariates, vaspin and 
adiponectin were measured. The influence of age on plasma 
vaspin was analysed using SPSS 13.0.
Results Vaspin increased with ageing, with mean vaspin 
levels (ng/mL) of 1.01 ± 2.25, 1.67 ± 2.95, 2.05 ± 3.46 
and 2.40 ± 3.06 for those between quartile ages 19–35, 
36–50, 51–65 and 66–80 years. When divided into sub-
groups, vaspin increased with increasing age for both 
sexes, both insulin resistance and non-insulin resistance 
subjects and both obese and lean subjects. In univariate 
analyses, vaspin plasma level positively associated with 
age (r = 0.215, p = 0.003), adiponectin, insulin, homoeo-
stasis model of assessment for insulin resistance index and 
waist–hip ratio in the whole population. The correlation 
between ageing and increasing vaspin remained significant 
after multivariate adjustments for factors such as sex, body 
mass index, waist–hip ratio, indices of glucose metabolism, 
white blood cell, lipid profile and adiponectin. Stepwise 
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increase in fat mass and a redistribution of adipose tissue 
from peripheral to central fat depots [5]. Adipokine dysreg-
ulation, as a common ground for insulin resistance, is also 
paradoxically correlated with lipodystrophy and lipoatro-
phy with ageing [6]. A recent study, which used centenar-
ians as a model of healthy ageing and longevity, also sug-
gests that adipose tissue excess as well as its ageing would 
regulate the expression of adipokines [7].
Vaspin is an interesting adipocytokine with insulin-
sensitizing effects [8–10]. Accumulating data implied that 
vaspin represents a compensatory mechanism in the devel-
opment of obesity and metabolic disorders [8, 11–13]. Up-
regulation of vaspin may have a protective effect against 
insulin resistance [9, 10, 14]. Central vaspin administra-
tion leads to reduced food intake and has sustained blood 
glucose-lowering effects [15]. As basic studies reported, it 
could suppress the expression of several inflammatory fac-
tors such as tumour necrosis factor (TNF)-α, leptin, resistin 
and adiponectin [10, 16], inhibit TNF-α-induced expres-
sion of adhesion molecules in vascular smooth muscle cells 
and blunt later lymphocyte adhesion [17], inhibit prolifera-
tion, chemokinesis and reactive oxygen species production 
of vascular smooth muscle cells [18, 19], and also protect 
vascular endothelial cells against free fatty acid-induced 
apoptosis [20]. Improved insulin resistance, attenuated 
inflammation and anti-apoptosis suggest that vaspin has a 
protective function.
Although previous studies suggested there may be some 
correlation between age and circulating vaspin level, the 
results were ambiguous and indefinite. Some have shown 
an age-related increase [13, 21–24], whereas others found 
no effect [25, 26] or even an age-related decrease [27] in 
serum vaspin concentrations. The contradiction may due 
to different experimental design and study population with 
narrow-spectrum ages. This paper was designed to examine 
the correlation between plasma vaspin level as a continuous 
variable and age, in a well-characterized, wide age-ranged, 
healthy group of Chinese people. We also determined 
whether any age-related changes in plasma vaspin were 
explained by metabolic syndrome components, adiposity-




The subjects included 191 individuals (106 men and 85 
women) who underwent complete medical check-ups at 
the Physical Checkup Centre at Shanghai Tenth People’s 
Hospital (China). The subjects included in this study were 
representative of normal Chinese people because they were 
patients who had not attended our hospital, who had no 
apparent disease that required hospital admission, and peo-
ple were all ages and occupations. People who were diag-
nosed as diabetes mellitus, hypertension or dyslipidaemia, 
or receiving any medications that affect blood pressures, 
body weight, glucose and lipid levels were excluded. Sub-
jects were considered to have hypertension if they had a 
mean systolic blood pressure (SBP) ≥140 mmHg and/or 
diastolic blood pressure (DBP) ≥90 mmHg and/or used 
anti-hypertensive medications. Diabetes was diagnosed 
according to the WHO criteria. Exclusion criteria for all 
study participants also include smoking, pregnancy, acute 
infection, hepatic dysfunction or renal dysfunction, neo-
plasm, haematologic disorders. Those who consumed 
at least one cigarette per day were considered smokers. 
Subjects who had never or stopped smoking during the 
last 12 months after years of smoking were considered 
non-smokers. All study participants were given written 
informed consent, and the study protocol was approved by 
Shanghai Tenth Hospital’s Ethics Committee.
Anthropometric and clinical assessments
All study participants underwent a standard clinical 
examination. A trained interviewer gathered information 
regarding medical history and current medication use. 
Height and body mass were recorded using a stadiometer 
attached to a scale. Weight was obtained with participants 
wearing light clothing and no shoes. Waist circumference 
measurements were made using a cloth tape measure at 
the level of the umbilicus. Hip girth was measured as the 
horizontal circumference at the broadest part of the lower 
body, usually at the level of the trochanters. BMI was cal-
culated as weight divided by the square of height. In the 
present analyses, we assigned individuals to non-obese 
and obese subgroups based on a modified cut-off value of 
BMI ≥ 25.0 kg/m2 for classification of obesity from an 
Asia-Pacifica perspective. The index of insulin resistance 
was assessed using the homoeostasis model of assessment–
insulin resistance [28] (HOMA-IR), as HOMA-IR = [fast-
ing insulin (μU/mL) × fasting glucose (mM)]/22.55 [29]. 
Insulin resistance (IR) was defined as the levels of the 
HOMA-IR greater than 2.55 [29].
ELISA assays and biochemical investigations
5 mL whole blood samples is obtained from all of the nor-
mal subjects before their medical check-up (more precisely, 
it was after overnight fast), in tubes containing EDTA for 
adipokines and biochemical investigations. Blood sam-
ples were centrifuged at 1000g for 10 min. Plasma speci-
mens were then frozen and stored at −80 °C until analy-
sis. Human total adiponectin (R&D Systems, Minneapolis, 
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USA) and vaspin (Adipogen, Seoul, South Korea) plasma 
levels were measured with ELISAs which had been reported 
previously [26]. Fasting insulin concentrations were meas-
ured with a commercially available ELISA immunoassay 
kit (ALPCO Diagnostics, Salem, NH, USA). White blood 
cell count, high-sensitive C-reactive protein (hsCRP), fast-
ing plasma glucose (FPG), alanine aminotransferase (ALT), 
blood urea nitrogen (BUN) and lipid profiles including 
total cholesterol (TC), low-density lipoprotein cholesterol 
(LDL-C), high-density lipoprotein cholesterol (HDL-C), 
triglycerides (TG), uric acid (UA) and creatinine (Cr) were 
measured by colorimetric enzymatic assay systems (Roche 
MODULAR P-800, Swiss Confederation).
Statistical analysis
Subjects were divided into four groups based upon age 
quartile (19–35, 36–50, 51–65 and 66–80 years). Continu-
ous variables were described as mean ± SD. Categorical 
variables were presented as frequencies. Normal distri-
bution was verified with the Kolmogorov–Smirnov test. 
All variables were checked for normality and subjected 
to log10 transformations, if necessary, prior to statistical 
analyses, but the actual data were presented. Comparisons 
between groups were made using unpaired t tests, ANOVA 
or a nonparametric Mann–Whitney U test when appropri-
ate. Chi-square test or Fisher’s exact test was employed for 
nonparametric data. Spearman’s rank correlation test and 
multiple linear regression analyses were used to determine 
the degree to which the variance in plasma vaspin levels 
can be explained by single factors. A two-sided probability 
level of ≤0.05 was taken as significance. All analyses were 




The basic characteristics of the participants are shown in 
Table 1. There were 191 study participants that contained 
106 men (55.7 %) and 85 women (44.5 %). Mean ± SD age 
of the participants was 50 ± 17 years, ranged 19–80 years. 
Average of vaspin and adiponectin was 1.78 ± 2.99 ng/mL 
and 11.79 ± 8.91 μg/mL, respectively. The subjects were 
enrolled into the following four groups based upon the age 
quartiles: 19–35 (n = 48), 36–50 (n = 47), 51–65 (n = 48) 
and 66–80 (n = 48) years. Gender, lipid profile, hsCRP and 
insulin showed no difference among different age groups. 
BMI, waist–hip ratio, FPG, IR prevalence (IR in Table 1), 
HOMA-IR, both systolic and diastolic blood pressure were 
increased with age.
As expected, in total population analysis, mean cir-
culating vaspin levels were significantly higher in IR 
group (2.56 ± 3.69 ng/mL) compared non-IR group 
(1.48 ± 2.62 ng/mL) (p < 0.01) (Fig. 1b) and higher 
in females (2.01 ± 3.10 ng/mL) compared with males 
(1.61 ± 2.91 ng/mL) (p < 0.05) (Fig. 1c).
Plasma vaspin concentrations increased with age
For all participants combined, plasma vaspin levels 
increased with ageing (Fig. 1a), from 1.01 ± 2.25 ng/
mL for those aged 19–35 years to 1.67 ± 2.95 ng/mL 
for those aged 36–50 years, 2.05 ± 3.46 ng/mL for those 
aged 51–65 years and 2.40 ± 3.06 ng/mL for those aged 
66–80 years (r = 0.251, p < 0.001). When divided into sub-
groups, same trend had been found in both sexes (Fig. 1c), 
both IR and non-IR subjects (Fig. 1b) and both obese and 
lean subjects (Fig. 1d). As expected, plasma adiponectin 
were correlated with increasing age in total (Table 1) or 
sex-specific analyses (data not show).
Extremely elevated vaspin ascents with age
Using extremely elevated vaspin cut-off values of 7.66 ng/
mL (90 % cut point found in this study), the prevalence of 
extremely elevated vaspin was lowest in the 19–35 year 
age group at 6.3 % (3 patients), then subsequently gradu-
ally ascents to 8.5 % (4 patients), 12.5 % (6 patients) and 
14.6 % (7 patients) for each progressive age subcategory 
(r = 0.150, p = 0.038) (Fig. 1e).
Correlation of vaspin with baseline clinical variables 
and other biomarkers
In univariate analyses, vaspin plasma level is positively 
correlated with age (r = 0.215, p = 0.003), adiponectin, 
insulin, HOMA-IR and waist–hip ratio in the whole popu-
lation (Table 2). In HOMA-IR-specific analyses, vaspin 
plasma level is positively correlated with age (r = 0. 285, 
p = 0.002), TC, LDL-C, ALT and HOMA-IR (Fig. 1; 
Table 2) in non-IR group, while, in sex-specific analy-
ses, vaspin plasma level is positively correlated with age 
(r = 0.356, p = 0.001), ALT and adiponectin in women, 
and is positively related to insulin and HOMA-IR in men 
(Fig. 1; Table 2). In lean subjects, vaspin plasma level is 
positively correlated with age (r = 0.311, p < 0.001), 
waist–hip ratio, TC, LDL-C, FPG, ALT, adiponectin and 
HOMA-IR, while in obese subjects, it is correlated with 
FPG (Fig. 1; Table 2) negatively.
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Standard multiple regression analysis of vaspin plasma 
level
The results of a stepwise multiple regression analysis with 
vaspin as the dependent variable and age, BMI, waist–hip 
ratio, insulin, adiponectin, HOMA-IR, FBG, WBC, triglyc-
erides, HDL-C as independent variables are presented in 
Table 3. Model 1 evaluates the effects of BMI and waist–
hip ratio on plasma vaspin levels, which explained 17.1 % 
of the variance in vaspin levels. In Model 2, indices of 
glucose metabolism were introduced into the regression 
analysis which explained an additional 8.6 % on plasma 
vaspin level. In Model 3, adiponectin, WBC and lipid pro-
file were additionally explained 10.2 % on plasma vaspin 
level. And in Model 4, age was additionally introduced into 
the regression analysis to evaluate the combined effect on 
plasma vaspin concentrations, which altogether explained 
43.5 % of the variance in vaspin levels, with age contribut-
ing 7.6 % on plasma vaspin level.
Discussion
In this population-based, wide age-ranged, normal group 
of Chinese people, plasma vaspin concentration increased 
with ageing for both sexes, both IR and non-IR subjects 
and both obese and lean subjects. The correlation between 
rising age and increasing vaspin remained significant even 
after multivariate adjustments for factors such as sex, 
BMI, waist–hip ratio, indices of glucose metabolism, lipid 
profile and adiponectin. The prevalence of extremely ele-
vated vaspin was also increased with increasing age quar-
tiles. These results suggest that the age-related increase 
in plasma vaspin levels is a common phenomenon in nor-
mal subjects and that age was an independent predictor of 
plasma vaspin level.
Ageing is related to fat redistribution, which is charac-
terized by loss of peripheral subcutaneous fat and accumu-
lation of central fat. Age-related fat loss or lipoatrophy is a 
major factor for adipose tissue dysfunction in centenarians 
Table 1  Clinical and 
biochemical characteristics of 
the study population
Continuous variables were described as mean ± SD; categorical variables were presented as frequencies
SBP systolic blood pressure, DBP diastolic blood pressure, n number of patients, BMI body mass index, 
LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglycerides, 
TC total cholesterol, FPG fasting plasma glucose, ALT alanine aminotransferase, BUN blood urea nitrogen, 
Cr serum creatinine concentrations, WBC white blood cells count, hsCRP high-sensitive CRP, HOMA-IR 
homoeostasis model of assessment–insulin resistance
Parameter Age quartiles
19–35 (n = 48) 36–50 (n = 47) 51–65 (n = 48) 66–80 (n = 48) p value
Male [n (%)] 24 (50 %) 22 (47.8 %) 35 (72.9 %) 25 (52.1 %) 0.332
IR [n (%)] 9 (18.8 %) 13 (27.7 %) 14 (29.2 %) 16 (33.3 %) 0.116
BMI (kg/m2) 21.24 ± 2.79 24.10 ± 3.36 24.48 ± 2.56 24.22 ± 2.80 <0.001
Waist–hip ratio 0.81 ± 0.65 0.83 ± 0.10 0.87 ± 0.85 0.87 ± 0.10 0.002
SBP (mmHg) 117 ± 12 130 ± 8 127 ± 8 128 ± 9 <0.001
DBP (mmHg) 72 ± 10 82 ± 9 80 ± 9 75 ± 10 <0.001
TC (mmol/L) 4.41 ± 1.02 4.82 ± 1.12 4.67 ± 1.00 4.68 ± 0.83 0.250
HDL-C (mmol/L) 1.26 ± 0.31 1.22 ± 0.31 1.19 ± 0.25 1.13 ± 0.20 0.203
LDL-C (mmol/L) 2.51 ± 0.76 2.78 ± 0.73 2.66 ± 0.69 2.64 ± 0.63 0.300
TG (mmol/L) 1.21 ± 0.69 1.64 ± 0.81 1.50 ± 0.78 1.48 ± 0.66 0.041
FPG (mmol/L) 4.70 ± 0.64 5.32 ± 0.70 5.25 ± 0.74 5.14 ± 0.77 <0.001
WBC (×109/L) 6.07 ± 1.24 5.81 ± 1.34 6.63 ± 1.51 6.41 ± 1.71 0.035
hsCRP (mg/L) 3.73 ± 2.05 6.69 ± 5.57 6.54 ± 5.93 6.59 ± 6.08 0.882
ALT (U/L) 14.82 ± 7.50 21.67 ± 15.80 26.26 ± 18.44 19.60 ± 13.21 0.002
BUN (mmol/L) 6.17 ± 8.32 6.85 ± 10.33 5.77 ± 1.19 6.73 ± 5.62 0.870
Cr (mg/L) 71.54 ± 30.64 76.72 ± 51.97 84.37 ± 47.74 85.22 ± 37.58 0.343
uric acid (mg/L) 312.45 ± 91.77 298.64 ± 108.06 350.99 ± 94.36 369.77 ± 110.61 0.002
Vaspin (ng/mL) 1.01 ± 2.25 1.67 ± 2.95 2.06 ± 3.49 2.40 ± 3.06 0.123
Adiponectin (μg/mL) 8.95 ± 5.76 10.45 ± 11.26 10.985 ± 6.34 16.78 ± 9.34 <0.001
Insulin (uIU/mL) 9.20 ± 5.32 9.47 ± 4.20 9.65 ± 3.86 10.30 ± 3.34 0.625
HOMA-IR 1.90 ± 1.06 2.26 ± 1.096 2.24 ± 0.93 2.35 ± 0.83 0.131
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Fig. 1  Plasma vaspin concentration in different age groups. a Plasma 
vaspin levels increased with increasing age in whole population. 
b Plasma vaspin concentrations according to age and insulin resist-
ance (IR: HOMA-IR greater than 2.5). c Plasma vaspin concentra-
tions increased with increasing age in different sex groups. d Plasma 
vaspin concentrations according to age in obese and lean groups. e 
The trend of increasing prevalence of extremely elevated vaspin with 
rising age
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Table 2  Correlations between vaspin and other variables in different subgroups
Data were represented as r (p value)
Bold and italic values indicate p values of correlations between vaspin and age in total and in subgroup of insulin resistance, which are no less 
than 0.05, but they can be considered to have statistical significance as they could be corrected by increased sample size
BMI body mass index, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglycerides, TC total cho-
lesterol, FPG fasting plasma glucose, ALT alanine aminotransferase, BUN blood urea nitrogen, Cr serum creatinine concentrations, WBC white 
blood cells count, hsCRP high-sensitive CRP, HOMA-IR homoeostasis model of assessment–insulin resistance
Parameters Total  
(n = 191)
Insulin resistance Sex Obese
IR (n = 53) Non-IR (n = 138) Male (n = 106) Female (n = 85) Obese (n = 55) Lean (n = 136)
Age 0.141 (0.052) 0.157 (0.050) 0.258 (0.002) 0.169 (0.084) 0.356 (0.001) 0.118 (0.390) 0.311 (<0.001)
Sex −0.053 (0.464) 0.115 (0.410) 0.092 (0.281) – – −0.068 (0.621) −0.097 (0.259)
BMI −0.046 (0.530) −0.267 (0.054) 0.042 (0.626) −0.002 (0.987) −0.002 (0.986) 0.159 (0.247) 0.022 (0.798)
Waist–hip ratio 0.171 (0.018) 0.144 (0.304) 0.149 (0.081) 0.157 (0.108) 0.178 (0.103) 0.122 (0.375) 0.170 (0.048)
TC 0.044 (0.594) −0.115 (0.414) 0.234 (0.006) −0.006 (0.948) 0.191 (0.081) −0.194 (0.156) 0.279 (0.001)
Triglycerides 0.015 (0.841) −0.086 (0.540) 0.126 (0.140) −0.034 (0.732) 0.117 (0.284) −0.137 (0.317) 0.161 (0.061)
HDL-C −0.018 (0.806) 0.105 (0.455) −0.044 (0.606) 0.011 (0.912) −0.050 (0.650) −0.149 (0.277) 0.044 (0.609)
LDL-C 0.156 (0.031) −0.050 (0.724) 0.193 (0.023) 0.046 (0.643) 0.153 (0.163) −0.120 (0.381) 0.233 (0.006)
FPG 0.104 (0.152) 0.037 (0.795) 0.114 (0.181) 0.072 (0.466) 0.115 (0.294) −0.254 (0.061) 0.225 (0.008)
ALT 0.072 (0.324) −0.008 (0.953) 0.261 (0.002) 0.178 (0.068) 0.295 (0.006) −0.120 (0.383) 0.322 (0.001)
BUN −0.050 (0.494) 0.035 (0.806) 0.042 (0.626) 0.110 (0.261) 0.013 (0.906) 0.213 (0.119) −0.008 (0.982)
WBC −0.016 (0.111) −0.085 (0.546) −0.154 (0.072) −0.172 (0.079) −0.085 (0.440) −0.127 (0.356) −0.131 (0.128)
hsCRP −0.028 (0.842) 0.201 (0.440) −0.198 (0.254) −0.0.080 (0.703) 0.293 (0.139) 0.302 (0.196) 0.102 (0.578)
Insulin 0.051 (0.473) 0.151 (0.256) 0.150 (0.079) 0.171 (0.040) 0.181 (0.098) −0.049 (0.722) 0.116 (0.117)
Adiponectin 0.184 (0.011) 0.436 (0.001) 0.129 (0.131) 0.182 (0.061) 0.206 (0.049) 0.207 (0.129) 0.191 (0.026)
HOMA-IR 0.161 (0.026) 0.144 (0.282) 0.147 (0.046) 0.161 (0.039) 0.189 (0.084) −0.126 (0.360) 0.184 (0.032)
Table 3  Standard multiple 
regression analysis for the 
impact of age and other 
potential confounders on vaspin 
levels
BMI body mass index, FPG fasting plasma glucose, HOMA-IR homoeostasis model of assessment–insulin 
resistance, LDL-C low-density lipoprotein cholesterol, WBC white blood cells
Independent variables Non-standardized β-coefficients 95 % CI p value
Model 1 (R2 = 0.171, F = 2.844, p = 0.061)
 BMI 0.062 0.016 to 0.108 0.008
 Waist–hip ratio 1.790 0.468 to 3.112 0.008
Model 2 (R2 = 0.257, F = 2.612, p = 0.026)
 Model 1 plus
 Insulin −0.087 −0.220 to 0.046 0.200
 FBG −0.163 −0.438 to 0.112 0.245
 HOMA-IR 0.453 −0.148 to 1.053 0.139
Model 3 (R2 = 0.359, F = 2.402, p = 0.008)
 Model 2 plus
 Adiponectin 0.231 −0.093 to 0.555 0.161
 TG 0.132 −0.026 to 0.291 0.101
 LDL-C 0.171 −0.100 to 0.442 0.215
 WBC −0.084 −0.149 to −0.019 0.012
Model 4 (R2 = 0.435, F = 3.454, p < 0.001)
 Model 3 plus
 Age 0.174 0.080 to 0.269 <0.001
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[7]. Moreover, adipokine dysregulation is paradoxically 
correlated with lipodystrophy and lipoatrophy with age-
ing [6]. Increments in fat mass especially visceral fat and 
hyperinsulinemia may modulate vaspin expression and 
release [8, 9, 12]. In analysis of our population charac-
teristics, BMI, waist–hip ratio and adiponectin increased 
with age, suggesting that central obesity increased with 
age. Since plasma vaspin significantly correlated with age, 
waist–hip ratio, fasting plasma insulin concentration and 
HOMA-IR, it is conceivable that with ageing, which is 
typically associated with alterations in body fat distribution 
(increased proportion of visceral fat) and insulin resistance, 
vaspin expression would be up-regulated.
In addition, vaspin levels were found to be significantly 
correlated with some markers of lipid metabolism such as 
TC, TG and LDL-C, which indicates that vaspin may be 
induced by dyslipidemia as a compensatory mechanism, 
especially because vaspin is an adipokine secreted by adi-
pocytes. The latest literatures reported that vaspin could 
activate cell surface GRP78 complex [30]. And GRP78 
expression and activity are declined with ageing [31]. So 
another possible interpretation for the age-related increase 
in plasma vaspin levels is positive feedback due to down-
regulation or resistance of vaspin receptors with age, but 
we could not measure vaspin receptors in this study to 
investigate this possibility. It has been reported that vaspin 
levels are negatively correlated with serum follicle-stim-
ulating hormone levels, sex hormone-binding globulin 
levels and positively correlated with free androgen index 
in women with polycystic ovary syndrome [27]. Our pre-
sent study found that plasma vaspin increased in both 
males and females but to a smaller extent in males. The 
sexual dimorphism in the levels of circulating vaspin also 
had been found previous study [12, 21, 26]. Therefore, 
another plausible explanation of the age-related increase 
in plasma vaspin levels is a decrease in sex hormones with 
age. Our finding that plasma vaspin levels were signifi-
cantly increased in subjects >50 years old supported this 
hypothesis.
Ageing is often accompanied by reduced insulin sen-
sitivity. A relationship between vaspin with insulin and 
HOMA-IR was observed in the current study. Previous 
study also reported that circulating vaspin levels is sig-
nificantly correlated with insulin sensitivity in subjects 
with normal glucose tolerance [12] and in obese children 
[8], suggesting a defensive role of vaspin against insulin 
resistance. The reported insulin-sensitizing effect of vaspin 
on adipose tissue supports this possibility [10]. Previous 
studies reported that vaspin suppressed the expression of 
several inflammatory factors, such as tumour necrosis fac-
tor (TNF)-α, leptin and resistin [10, 16]. It also attenuated 
TNF-α-induced p65 phosphorylation, reduces intercellular 
adhesion molecule-1 expression and reactive oxygen spe-
cies production, inhibits vascular smooth muscle cells 
proliferation and chemokinesis [17–19], increased nitric 
oxide bioavailability in vascular endothelial cells [32], and 
protected vascular endothelial cells against free fatty acid-
induced apoptosis. Thus, high plasma vaspin levels in the 
elderly might have numerous beneficial effects because 
inflammation, atherosclerosis and apoptosis are advanced 
with age. Vaspin was positively associated with adiponec-
tin. Higher adiponectin levels are related to the longevity. 
However, it is still unclear whether higher plasma levels 
also related to the longevity.
The strengths of this study include the use of a population-
based, wide age-ranged, well-characterized group of normal 
people. Some limitations should be considered in this study. 
Firstly, this was a cross-sectional rather than a longitudinal 
study. The cross-sectional design made it difficult to deter-
mine the causality of observed relationships. In addition, we 
did not assess habitual physical activity and menopausal sta-
tus, which may affect vaspin and adiponectin levels.
In conclusion, vaspin level was not constant, but 
increased with increasing age, independent of sex, indi-
ces of glucose metabolism, surrogate markers of adipos-
ity, lipid profile and other markers of adiposity such as 
adiponectin. On the basis of these results, vaspin might be 
used as a predictor of cardiovascular disease in the future; 
we consider that clinicians should take into account age-
related changes in plasma vaspin levels when interpreting a 
patient’s plasma vaspin level in clinical practice.
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